Aimmune Therapeutics
8000 Marina Boulevard
Suite 300
Brisbane
California
94005-1884
United States
About Aimmune Therapeutics
179 articles with Aimmune Therapeutics
-
Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
4/8/2020
Aimmune Therapeutics to Present at the 19 th Annual Needham Virtual Healthcare Conference
-
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
3/16/2020
Aimmune Therapeutics, Inc. today announced that the first patients in the United States are being treated with PALFORZIA™ [Peanut ( Arachis hypogaea ) Allergen Powder-dnfp], the first approved treatment for peanut allergy. Following the release of the medication lots by the U.S. Food an
-
Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of Treatment
3/13/2020
Additional Data Highlight PALISADE Study Patient Baseline Characteristics and Associated Treatment Response — and Improvements in Self-Reported Quality of Life Following Long-Term Treatment with PALFORZIA
-
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights
2/27/2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), today announced financial results for the fourth quarter and full year 2019.
-
Aimmune Therapeutics to Present at Upcoming Investor Conferences
2/26/2020
Feb. 26, 2020 13:00 UTC BRISBANE, Calif.--( BUSINESS WIRE )-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will present at two upcoming investor conferences in March: Event: The 40 th Annual Cowen Health Care Conference Date: Tuesday, March 3, 2020 Presentation Time: 9:20 a.m. ET Location:
-
Aimmune to Present New Clinical Data at AAAAI Annual Meeting
2/25/2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced it will present new data from the clinical trial program for PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first-ever peanut allergy treatment approved by the U.S. Food and Drug Administration (FDA).
-
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
2/20/2020
Feb. 20, 2020 13:30 UTC BRISBANE, Calif.--( BUSINESS WIRE )-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Thursday, February 27, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2019, and recent operational highlights. To access the live call by phone,
-
Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science
2/5/2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that Nestlé Health Science will make an additional equity investment in Aimmune of $200 million, bringing Nestlé’s total investment in Aimmune to date to $473 million.
-
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
2/5/2020
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody XmAb®7195 to Aimmune Therapeutics, Inc.
-
Aimmune to Advance Development of Newly-Licensed Asset with $200 Million Investment from Nestle
2/5/2020
Aimmune announced a licensing deal with Xencor for the investigational humanized monoclonal antibody XmAb7195, which has been redubbed AIMab7195. -
For the millions of people suffering from an allergy to peanuts, there is a new, first-of-its-kind treatment available. On Friday, the U.S. Food and Drug Administration approved Aimmune Therapeutics’ oral immunotherapy AR101.
-
FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy
1/31/2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the U.S. Food and Drug Administration (FDA) approved PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp].
-
Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/6/2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 38th Annual J.P. Morgan Healthcare Conference
-
Aimmune to Participate in Three Upcoming Investor Conferences
11/15/2019
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in three upcoming investor conferences in November and December:
-
Clinical Catch-Up: November 4-8
11/11/2019
It was a busy week for clinical trial updates for the first week of November. Here’s a look. -
New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots
11/8/2019
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed that the logistical needs for implementing oral immunotherapy (OIT) for food allergies, such as peanut allergy, into clinical practice is comparable to those for subcutaneous immunotherapy (SCIT) for environmental allergies.
-
AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data
11/8/2019
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the results from a new analysis showing consistent efficacy and safety with AR101 across the phase 3 PALISADE and ARTEMIS trials, despite differing regions of study, entry criteria, therapeutic dosing periods and primary efficacy endpoints.
-
AR101 is an investigational, peanut-derived, biologic drug candidate for oral immunotherapy in patients with peanut allergy. It delivers a daily dose of peanut protein with a consistent protein profile.
-
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
-
Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights
11/6/2019
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, announced financial results for the quarter and nine months ended September 30, 2019 and provided operational highlights.